Tatva Chintan Q4 FY26: Revenue up 24%, EBITDA +214%

Results announced after board meeting

Tatva Chintan Pharma Chem Ltd (BSE: 543321) declared its Q4 FY26 results on May 16, 2026, for the quarter ended March 31, 2026. The company also said its financial results were submitted to stock exchanges and are available on its website.

For the quarter, Tatva Chintan reported a sharp year-on-year improvement in operating performance, supported by a better product mix and improved operating leverage. Segment performance was mixed, with a standout surge in Electrolyte Salts and a year-on-year decline in Phase Transfer Catalyst (PTC) revenue.

Q4 FY26 topline rises to INR 134.1 crore

Operating revenue for Q4 FY26 stood at INR 134.1 crore, up 24% year-on-year and 2% quarter-on-quarter. A separate quarterly table in the source data shows total revenue at INR 133.8 crore for the March 2026 quarter, broadly consistent with the company’s reported operating revenue.

The company also reported PAT (net profit) of INR 10.32 crore for the quarter. This compared with INR 1.03 crore in the same quarter last year, as per the quarterly table shared in the provided text.

EBITDA jumps on mix and operating leverage

EBITDA for Q4 FY26 was INR 28.1 crore, a 214% year-on-year increase and 10% sequential improvement. Management attributed the increase primarily to a better product mix and improved operating leverage.

The operating profit table in the provided data shows operating profit of INR 28.13 crore for the March 2026 quarter versus INR 8.95 crore a year ago, aligning with the stated 214% year-on-year increase.

Segment snapshot: Electrolyte Salts leads, PTC soft YoY

Tatva Chintan’s segment-wise performance showed strong divergence between product lines. Electrolyte Salts posted exceptional growth both sequentially and year-on-year, while PTC revenue declined year-on-year despite growing quarter-on-quarter.

Structure Directing Agents (SDA) delivered strong year-on-year growth, although revenue was marginally lower quarter-on-quarter. Pharma and Agro Intermediates and Specialty Chemicals grew year-on-year but declined sequentially.

Electrolyte Salts: sharp jump from a smaller base

Electrolyte Salts revenue rose to INR 13.1 crore in Q4 FY26. The company reported growth of 865% quarter-on-quarter and 1,378% year-on-year for this segment.

While the base was lower in earlier periods, the magnitude of growth made Electrolyte Salts the most prominent driver of incremental momentum in Q4 FY26. The segment’s performance stood out even as some other categories saw either sequential softness or year-on-year pressure.

Phase Transfer Catalyst: QoQ improvement but YoY decline

Phase Transfer Catalyst revenue was INR 31.1 crore in Q4 FY26. This marked 11% sequential growth, but revenue was down 20% year-on-year.

The combination suggests the segment improved from the immediately preceding quarter, but did not recover to last year’s levels. The provided text does not specify whether the year-on-year decline was driven by volume, pricing, or customer-level factors.

Other segments: SDA grows YoY; pharma-agro sees sequential decline

Structure Directing Agents revenue came in at INR 52.5 crore. The company reported a 2% quarter-on-quarter decline, but a 52% year-on-year increase.

Pharma and Agro Intermediates and Specialty Chemicals generated INR 35.8 crore in Q4 FY26. This was up 10% year-on-year, but down 24% sequentially, indicating that the segment’s quarterly run-rate softened compared with Q3 FY26.

Capacity update: Dahej block commercialised

Tatva Chintan said it successfully commercialised its new production block at the Dahej site. The commissioning is intended to enhance operational capacity, based on the company’s update in the provided text.

The company also flagged future growth initiatives linked to a new Jolva plant. It said it plans to launch two agro intermediates with “significant revenue potential” once Jolva becomes operational.

Full-year context: revenue crosses INR 500 crore

Management noted that the company achieved revenue in excess of INR 500 crore in the recently concluded financial year. In the detailed annual numbers provided, full-year FY26 revenue was reported at INR 509.4 crore, compared with INR 385.0 crore a year ago.

Full-year FY26 net income was INR 42.1 crore, compared with INR 5.7 crore in the previous year, as per the figures included in the text.

Key numbers table (normalised to INR crore)

Segment revenue table (Q4 FY26)

Market lens: rating and peer references

The provided text notes that one analyst has given the stock a sell rating. It also lists peers such as Asian Paints (+1.56%), Pidilite Industries (+0.61%), and Solar Industries India (-1.56%), without specifying the time period for these moves.

What investors may track next

Tatva Chintan disclosed that its earnings call post announcement of financial results for the quarter and year ended March 31, 2026, is scheduled on Saturday, May 16, 2026 at 5:00 p.m. IST. The call is hosted by ICICI Securities.

With Q4 showing a large EBITDA expansion and a sharp Electrolyte Salts jump alongside mixed performance in other segments, the next set of updates around Dahej utilisation and the timeline for the Jolva plant will remain important markers for operating execution.